Business Segments Eiger BioPharmaceuticals
Stocks
EIGR
US28249U2042
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.500 USD | -.--% |
|
-.--% | - |
| 24-10-01 | Eiger BioPharmaceuticals Files for Chapter 11 Bankruptcy as Liquidation Plan Takes Effect | CI |
| 24-09-30 | Eiger BioPharmaceuticals, Inc. Went Out of Business | CI |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Biotechnology (Startups) | - | - | 12.14M | 13.48M | 15.77M | |||||
Total Assets | 105M | 144M | 126M | 120M | 38.83M | |||||
Interest Expense | -3.41M | -3.59M | -3.56M | -4.13M | -5.47M | |||||
Income Tax Expense | - | - | 64K | 23K | 6K | |||||
CAPEX | -475K | -258K | -225K | -340K | -234K | |||||
EBT | -70.25M | -65.05M | -33.85M | -96.75M | -74.96M | |||||
D&A | 486K | 645K | 799K | 842K | 750K | |||||
Operating Income | -68.9M | -62.15M | -76.94M | -92.74M | -71.79M | |||||
Net Income | -70.25M | -65.05M | -33.92M | -96.78M | -74.96M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | - | - | 12.14M | 13.48M | 15.77M | |||||
Total Assets | 105M | 144M | 126M | 120M | 38.83M | |||||
Interest Expense | -3.41M | -3.59M | -3.56M | -4.13M | -5.47M | |||||
Income Tax Expense | - | - | 64K | 23K | 6K | |||||
D&A | 486K | 645K | 799K | 842K | 750K | |||||
CAPEX | -475K | -258K | -225K | -340K | -234K | |||||
Net Income | -70.25M | -65.05M | -33.92M | -96.78M | -74.96M | |||||
EBT | -70.25M | -65.05M | -33.85M | -96.75M | -74.96M | |||||
Operating Income | -68.9M | -62.15M | -76.94M | -92.74M | -71.79M |
- Stock Market
- Stocks
- EIGR Stock
- Financials Eiger BioPharmaceuticals
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
